Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib for Inhibition of Food-Induced Anaphylaxis
NCT03149315Phase 2Completed
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Apr 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in food allergy, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Primary endpoint: Number of Doses of Ibrutinib for Maximal Suppression of Skin Prick Test Size to Foods at 7 days. Started Apr 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT03149315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149315.